Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (<scp>SV</scp>2A) ligand with preclinical evidence of high brain permeability and fast onset of action

Abstract

These preclinical data demonstrate that BRV has rapid brain entry and fast brain SV2A occupancy, consistent with the fast onset of action in the audiogenic seizure mice assay. The potential benefit of BRV for treatment of acute seizures remains to be confirmed in clinical studies.